The Dark Side of Patient Advocacy on Social Media
PodcastDX
The dark side of advocacy is that the same social media platforms that help health advocates reach millions can also expose them to relentless trolls, coordinated pile‑ons, and even threats to their safety and careers. Studies of physicians and public‑health advocates show that a large share—sometimes more than half—have been personally attacked online for speaking about vaccines, gun violence, or other health issues, facing abuse that targets not just their ideas but also their gender, race, disability, or identity. What starts as “just comments” can quickly escalate into doxxing,...
info_outline
Cancer Care in Transition
PodcastDX
In this week’s episode, “Cancer Care in Transition: Precision Medicine, Immunotherapy, and Patient Choice,” we look at how cancer treatment is changing at the exact moment when patients are trying to move from crisis mode into something like a new normal. Precision medicine now uses a person’s genes, tumor markers, and even lifestyle to match them with targeted drugs or immunotherapies instead of one‑size‑fits‑all chemo, while immuno‑oncology has created a growing group of survivors living with long‑term effects and unique follow‑up needs. At the same time,...
info_outline
Various Types of Dementia
PodcastDX
Various Types of Dementia This week on PodcastDX, we’re stepping into the complex world of dementia—not as a single diagnosis, but as a family of conditions that affect memory, thinking, behavior, and independence in different ways. We’ll introduce the most common types of dementia, including Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and mixed dementia, where more than one process—often Alzheimer’s plus vascular changes—are happening in the brain at the same time. We’ll also touch on less common causes, such as dementia related to...
info_outline
Rethinking DX: A Digital DSM and the Roots of Mental Health
PodcastDX
“Rethinking DX: A Digital DSM” looks at how the Diagnostic and Statistical Manual of Mental Disorders (DSM) quietly shapes almost every part of mental health care—from who gets a diagnosis and insurance coverage to how people understand their own symptoms and identities. In this conversation, Lita and Jean Marie unpack what the DSM actually is, why the current DSM‑5‑TR matters, and how a future, fully digital “DSM‑6” could function as a living document that updates more quickly, links to decision‑support tools, and better integrates real‑world data from electronic health...
info_outline
The Next Decade in Medicine
PodcastDX
Over the next decade, medicine won’t just add new gadgets—it will change what it feels like to be a patient. In this episode of PodcastDX, we explore how AI as a clinical co‑pilot, stem cells and regenerative medicine, genomics and precision care, wearables, and hospital‑at‑home models could reshape everyday care. We talk about the promise of earlier detection and more personalized treatment, the risks around bias, privacy, and hype, and why equity and shared decision‑making must stay at the center as technology races ahead. Most of all, we ask how patients and caregivers can be...
info_outline
Patients as Partners: Shared Decision Making in Medicine
PodcastDX
This week we are discussing the rise of a new type of health care where the patients play a vital role in their medical care. Patients as partners in care are at the heart of shared decision making (SDM), a model where clinicians and patients deliberately work together to choose tests and treatments that fit both best evidence and the patient’s values and life context. What shared decision making means SDM is a collaborative process in which clinicians contribute clinical expertise while patients contribute their goals, preferences, and lived experience. Core...
info_outline
End of Life in Transition: Earlier Palliative Care, Better Conversations
PodcastDX
At a time when modern medicine is allowing people to enjoy longer, fuller lives, mortality is not always a chief concern. But when a serious illness occurs, the topic becomes unavoidable. This became especially clear during the early days of the COVID-19 pandemic when hospitals were overrun with patients, many with grim prognoses. “The pandemic gave all of us a sense that life can be short and there’s the very real possibility of dying,” says , director of the Palliative Care Program at Yale New Haven Hospital. “It opened the door for us to talk more about death and have a...
info_outline
Is Mental Health Care Changing Fast Enough
PodcastDX
This week we discuss the current status of Mental Health Care. Mental health care is changing, but most experts argue it is not changing fast enough relative to the need, especially on access, equity, and workforce. Where change is too slow Unmet need is huge. In the U.S., millions with a diagnosable condition still receive no treatment each year; a recent national report notes that many adults with mental illness remain uninsured or unable to access care. Global workforce shortages. Nearly 50% of the world’s population lives in countries with fewer...
info_outline
Rehabilitation Reimagined: Technology, Therapy and Independence
PodcastDX
The integration of Artificial Intelligence (AI) into post-injury rehabilitation is transforming recovery paradigms by enabling personalized, adaptive, and efficient rehabilitation pathways tailored to individual patient needs. This podcast reviews the current advances in AI applications that facilitate assessment, monitoring, and optimization of rehabilitation programs following injuries. Through machine learning algorithms, wearable sensors, and predictive analytics, AI enhances the precision of therapy plans, tracks patient progress in real-time, and predicts recovery trajectories. The...
info_outline
The Gut Brain Revolution
PodcastDX
The gut–brain revolution is about treating the digestive system and the nervous system as one integrated network instead of two separate organs that happen to share a body. The gut–brain axis is a bidirectional communication system: the brain influences digestion, motility, and gut sensation, while the gut and its microbiota send chemical, neural, and immune signals back to the brain that can shape mood, cognition, and even neurodegeneration. Central to this loop is the vagus nerve, the longest cranial nerve, which carries most of the traffic from gut to brain and...
info_outlineThis week we will discuss M-RNA vaccines. Our guest is Thomas VanCott, PhD. Thomas VanCott is currently the Chief Scientific Officer for Combined Therapeutics, a Boston based biotech company developing targeted mRNA therapies. Prior to this he served as the Chief Technology and Strategy Officer for Catalent Cell & Gene Therapy, a global CDMO manufacturing viral vectors for gene and cell therapies as wells as plasmid DNA & mRNA platforms based in Baltimore, MD. He was responsible for strategically enhancing CMC services to meet the market demand of increasingly complex gene and cell therapy products as well as leading the product development and internal R&D teams. Prior to this, he was the CEO for 10 years at a Maryland-based CMO/CRO (ABL) where he was responsible for the strategic international growth of the company. He has been involved in biologics product development for over 25 years. He has a PhD in physical chemistry and started his career as a Captain in the US Army stationed at Walter Reed Army Institute of Research (WRAIR) studying and developing HIV vaccines for international deployment from initial construction through preclinical development, GMP manufacturing and clinical development.
Vaccines help prevent infection by preparing the body to fight foreign invaders (such as bacteria, viruses, or other pathogens). All vaccines introduce into the body a harmless piece of a particular bacteria or virus, triggering an immune response. Most vaccines contain a weakened or dead bacteria or virus. However, scientists have developed a new type of vaccine that uses a molecule called messenger RNA (mRNA) rather than part of an actual bacteria or virus. Messenger RNA is a type of RNA that is necessary for protein production. Once cells finish making a protein, they quickly break down the mRNA. mRNA from vaccines does not enter the nucleus and does not alter DNA.
mRNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein, usually a small piece of a protein found on the virus’s outer membrane. (Individuals who get an mRNA vaccine are not exposed to the virus, nor can they become infected with the virus by the vaccine.) By using this mRNA, cells can produce the viral protein. As part of a normal immune response, the immune system recognizes that the protein is foreign and produces specialized proteins called antibodies. Antibodies help protect the body against infection by recognizing individual viruses or other pathogens, attaching to them, and marking the pathogens for destruction. Once produced, antibodies remain in the body, even after the body has rid itself of the pathogen, so that the immune system can quickly respond if exposed again. If a person is exposed to a virus after receiving mRNA vaccination for it, antibodies can quickly recognize it, attach to it, and mark it for destruction before it can cause serious illness.
Like all vaccines in the United States, mRNA vaccines require authorization or approval from the Food and Drug Administration (FDA) before they can be used. Currently vaccines for COVID-19, the disease caused by the SARS-CoV-2 coronavirus, are the only authorized or approved mRNA vaccines. These vaccines use mRNA that directs cells to produce copies of a protein on the outside of the coronavirus known as the “spike protein”. Researchers are studying how mRNA might be used to develop vaccines for additional diseases. (credits: Medline Plus)